Aminobenzoic acids and derivatives
Medchemexpress LLC Cp-506 mesylate | 2227304-19-8 | 98.6% | 681.60 | 5 MG
Cp-506 mesylate is a light yellow to yellow solid. This product has been tested and complies with the given specifications. It is important to note that this product has not been fully validated for medical applications and is intended for research use only.
- Cas number: 2227304-19-8
- Molecular weight: 681.60
- Purity: 98.59%
- Storage conditions for powder: -20°C for 3 years, 4°C for 2 years
- Storage conditions in solvent: -80°C for 6 months, -20°C for 1 month
Apexbio Technology LLC KB-R7943 mesylate 182004-65-5 50mg
KB-R7943 mesylate (CAS 182004-65-5) is a selective inhibitor of the Na /Ca2 exchanger (NCX) particularly effective against its reverse mode It inhibits NCX-mediated Ca2 influx with an IC50 of 0 7 M In transfected Chinese hamster ovary (CHO) cells expressing NCX KB-R7943 suppresses exchanger activity at high intracellular Na concentrations In cultured rat forebrain neurons it attenuates Ca2 transients induced by glutamate NMDA kainate or KCl with IC50 values ranging from 2 9 to 8 2 M In in vivo studies KB-R7943 reduces endothelin-1 levels and mitigates acute renal dysfunction following ischemic injury This compound is widely utilized in studies investigating Na /Ca2 exchange and related calcium signaling pathways
Medchemexpress LLC Nafamostat formate salt-13C6 | 98.1% | 1 MG
Nafamostat formate salt-13C6 is a 13C labeled Nafamostat, a synthetic serine protease inhibitor and anticoagulant. It suppresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis, and also blocks activation of SARS-CoV-2. This compound is intended for research use only.
- Can be used as a tracer.
- Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
- Features a 13C labeled structure.
- Acts as a synthetic serine protease inhibitor.
- Functions as an anticoagulant.
- Suppresses T cell auto-reactivity.
- Blocks activation of SARS-CoV-2.
Apexbio Technology LLC Trovafloxacin mesylate 147059-75-4 50mg
Trovafloxacin mesylate (CAS 147059-75-4) is a small-molecule inhibitor targeting bacterial DNA topoisomerase IV and DNA gyrase It is designed to interfere with DNA replication and transcription thereby inhibiting bacterial DNA synthesis Trovafloxacin mesylate exerts its biological activity primarily through stabilization of the quinolone-DNA-enzyme complex leading to inhibition of DNA synthesis in bacterial cells In enzymatic assays Trovafloxacin mesylate demonstrates inhibitory activity with IC50 values typically within the nanomolar to low micromolar range depending on bacterial targets and assay conditions Based on these pharmacological properties Trovafloxacin mesylate holds research potential in antibacterial mechanism analysis resistance pathway examination and pharmacological profiling against both Gram-positive and Gram-negative bacteria
Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | 98.06% | 658.81 | 50 MG
Naquotinib mesylate is an orally available, mutant-selective and irreversible EGFR inhibitor. It shows potent inhibition against EGFR mutants with IC50s of 8-33 nM, and 230 nM for wild-type EGFR. It has demonstrated efficacy in inhibiting cell growth and inducing tumor regression in various xenograft models.
- Orally available and mutant-selective
- Irreversible EGFR inhibitor
- Potent inhibition of EGFR mutants (8-33 nM IC50)
- Inhibits phosphorylation of EGFR and downstream signaling pathways (ERK and Akt)
- Induces tumor regression in xenograft models
Medchemexpress LLC Eprosartan mesylate | 144143-96-4 | MFCD08141807 | 100.0% | 520.62 g/mol | C24H28N2O7S2 | 10 MG
Eprosartan mesylate is a selective, competitive, orally active angiotensin II receptor antagonist supplied for research use in pharmacology and biochemical studies. It is provided as a high-purity solid and as solution formulations for in vitro assays, and is supported by technical documentation (datasheet, COA, SDS) for laboratory handling and experimental planning.
- Selective angiotensin II receptor antagonist suitable for receptor binding and functional assays.
- High purity appropriate for research applications (listed at 99.95%).
- Available as a solid and as a 10 mM solution in DMSO for in vitro use.
- Supported by datasheet, certificate of analysis, and safety data sheet.
- Stable when stored sealed and protected from moisture; specific solvent storage conditions available.
Apexbio Technology LLC Delavirdine mesylate 147221-93-0 100mg
Delavirdine mesylate (CAS 147221-93-0) is a small-molecule inhibitor targeting HIV-1 reverse transcriptase It is designed to selectively inhibit the enzymatic activity of HIV-1 reverse transcriptase thereby disrupting viral DNA synthesis and impeding HIV replication Delavirdine mesylate exerts its biological activity primarily through direct binding to an allosteric site on HIV-1 reverse transcriptase In biochemical studies delavirdine mesylate demonstrates inhibitory activity against HIV-1 reverse transcriptase with an IC50 value of 0 26 M Based on these pharmacological properties delavirdine mesylate holds research potential in antiviral assays HIV resistance studies and mechanistic investigations into NNRTI-related enzyme inhibition
AdipoGen Talabostat mesylate
Chemical. CAS 150080-09-4. Formula C9H19BN2O3 . CH4O3S. MW 310.2. Talabostat is an orally bioavailable non-selective inhibitor of dipeptidyl-peptidases DPPs, including DPP-4, DPP-7/QPP, DPP-8, DPP-9, fibroblast activation protein FAP and prolyl endopeptidase PREP PEP IC50s = >4, 310, 4, 11, 560 and 390 nM, respectively. Talabostat induces powerful anti-tumor immune responses in cancer models. Talabostat is a NLRP1 and caspase recruitment domain family member 8 CARD8 inflammasome activator. Talabostat triggers an immunostimulatory form of programmed cell death known as pyroptosis selectively in monocytes and macrophages. DPP8/9 inhibition by Talabostat activates the inflammasome sensor protein Nlrp1b, which in turn activates pro-caspase-1 to mediate pyroptosis, suggesting that DPP8/9 serve as an intracellular checkpoint to restrain Nlrp1b and the innate immune system.
Medchemexpress LLC Pritelivir mesylate | 1428333-96-3 | 99.5% | 498.60 g·mol⁻¹ | C19H22N4O6S3 | 10 MG
Pritelivir mesylate is the mesylate salt of pritelivir, a small-molecule inhibitor of the herpes simplex virus helicase-primase complex. It demonstrates potent antiviral activity in vitro against HSV-1 and HSV-2 (reported IC50 ≈ 0.02 μM) and is intended for research use in antiviral and virology studies.
- Inhibits the viral helicase-primase complex, reducing HSV replication.
- Potent in vitro activity with low-nanomolar IC50.
- High reported purity suitable for biochemical and cell-based assays.
- Supplied as a mesylate salt for improved stability and solubility handling.
- Available in small research quantities for preclinical experimentation.
Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | MFCD30496702 | 98.2% | 658.81 | C31H46N8O6S | 10 MG
Naquotinib mesylate is the mesylate salt of naquotinib, an orally available, irreversible, mutant-selective epidermal growth factor receptor (EGFR) inhibitor used in preclinical research. It preferentially inhibits common activating and resistance EGFR mutants while showing reduced potency against wild-type EGFR, making it useful for studies of mutant-selective signaling and resistance mechanisms.
- Mutant-selective irreversible EGFR inhibitor
- Potent against L858R, exon 19 deletion, and T790M mutants (IC50 8-33 nM)
- Lower potency toward wild-type EGFR (IC50 ~230 nM)
- Provided as a mesylate salt suitable for research applications
- Molecular formula C31H46N8O6S; molecular weight 658.81
- Reported research-grade purity approximately 98%
Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | 98.1% | 658.81 | 1 ML
Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective, and irreversible EGFR inhibitor. It demonstrates potent inhibitory activity against EGFR mutants, with IC50 values ranging from 8 to 33 nM, while showing an IC50 of 230 nM for wild-type EGFR. This compound is primarily used in research contexts involving EGFR inhibition.
- Orally available
- Mutant-selective
- Irreversible EGFR inhibitor
![eMolecules 169869-90-3 | Exatecan mesylate | Ambeed | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000126098.jpg-250.jpg)
eMolecules 169869-90-3 | Exatecan mesylate | Ambeed | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076
Exatecan mesylate | Ambeed | 169869-90-3 | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076
Medchemexpress LLC AZ7550 Mesylate | 2319837-99-3 | 98.7% | 100 MG
AZ7550 Mesylate is an active metabolite of AZD9291 that inhibits IGF1R activity with an IC50 of 1.6 μM. This product is intended for research use only.
- Inhibits IGF1R with an IC50 of 1.6 μM.
- Shows potency and selectivity profile similar to AZD9291.
- Inhibits DM cell line H1975, AM cell line PC9, and WT cell line LoVo.
- Inhibits DM antiproliferative cell line H1975, AM cell line PC9, and WT antiproliferative cell line Calu3.
Medchemexpress LLC Masitinib mesylate | 1048007-93-7 | MFCD12546334 | 100.0% | 594.75 g/mol | C29H34N6O4S2 | 100 MG
Masitinib mesylate is the mesylate salt of masitinib, a selective, orally bioavailable tyrosine kinase inhibitor targeting c-Kit and related kinases. It is supplied as a research-grade analytical standard for preclinical and in vitro studies, with high purity and characterized physicochemical properties.
Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | 98.1% | 658.81 | 25 MG
Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective, and irreversible EGFR inhibitor that demonstrates inhibitory concentrations (IC50s) ranging from 8 to 33 nM against EGFR mutants and 230 nM for wild-type EGFR. It effectively inhibits the growth of various EGFR-dependent non-small cell lung cancer cell lines, including those with exon 19 deletion and T790M resistance mutations. The compound selectively targets the phosphorylation of EGFR and its downstream signaling pathways, such as ERK and Akt, at concentrations as low as 10 nM in sensitive cell lines. Additionally, oral administration of this compound induces dose-dependent tumor regression in several xenograft models.
- Orally available
- Mutant-selective EGFR inhibitor
- Irreversible EGFR inhibitor
- Inhibits phosphorylation of EGFR and downstream signal pathway, ERK and Akt
- Induces tumor shrinkage in EGFR mutated tumor models